Global Polycystic Ovary Syndrome Market, Condition (Irregular Periods, Excess Androgen, Polycystic Ovaries, Others), Complication (Infertility, Metabolic Syndrome, Sleep Apnea, Endometrial Cancer, Depression, Others), Diagnosis (Physical Exam, Pelvic Exam, Sonogram, Blood Tests, Others), Treatment (Medication, Surgery, Others), Route of Administration (Oral, Parenteral, Implants, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029
Polycystic Ovary Syndrome Market Analysis and Size
The global polycystic ovary syndrome market is expected to witness significant growth during the forecast period. Rising prevalence of reproductive hormones diseases in women’s, increased use of alcohol & drugs, increased depression & stress and increased awareness towards female reproductive health drive the polycystic ovary syndrome market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global polycystic ovary syndrome market in the forecast period 2022-2029. The expected CAGR of global polycystic ovary syndrome market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 3.4 billion in 2021, and it would grow upto USD 5.02 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Polycystic ovary syndrome (PCOS) is common health problem among the females usually caused by imbalance of reproductive hormones. Females having PCOS may excess male hormones (androgens) and have infrequent & prolonged irregular menstrual periods. 27% of females can be affected by the PCOS during their childbearing years.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Condition (Irregular Periods, Excess Androgen, Polycystic Ovaries, Others), Complication (Infertility, Metabolic Syndrome, Sleep Apnea, Endometrial Cancer, Depression, Others), Diagnosis (Physical Exam, Pelvic Exam, Sonogram, Blood Tests, Others), Treatment (Medication, Surgery, Others), Route of Administration (Oral, Parenteral, Implants, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries (Israel), Mitsubishi Chemical Group Corporation (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Par Pharmaceutical (U.S.), TerSera Therapeutics LLC (U.S.), General Electric (U.S.), Koninklijke Philips N.V. (Netherlands), Allergan (Ireland), Alcon (Switzerland), Astellas Pharma Inc. (Japan)
|
|
Market Opportunities
|
|
Global Polycystic Ovary Syndrome Market Dynamics
Drivers
- Increasing Prevalence of PCOS
According to the study published in September 2019, the prevalence of polycystic ovarian syndrome(PCOS) in adolescents was found to be 11.04%, it was 3.39% based on the National Institute of Health’s criteria and 8.03% worldwide based on the Androgen Excess and Polycystic Ovary Syndrome Society. This boost the market growth.
- Rising Healthcare Expenditure
Since the last few decades, it has been witnessed that global per capita healthcare spending has improved considerably due to rising rate of awareness associated with the availability of treatments and diagnostic methods for treating various diseases. More and more healthcare spending is likely to result in increasing demand for better diagnostic methods, which in turn, create high growth opportunities for market players operating in the treatment of hormonal infertility.
Opportunities
- Increasing Demand for Retail Pharmacies
The rise in the number of polycystic ovary syndrome medications delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Rising Demands of Insulin Sensitizing Agents
There are various drugs that are used for polycystic ovarian syndrome which are in high demand. Currently, only Metformin, which is an insulin sensitizing agent has been included in the list of reimbursed medicines. All these factors are on the rise and are increasing, thus expanding growth.
Restraints/Challenges
- Lack of Female Reproductive Health Awareness
Lack of female reproductive health awareness in most of the economic countries may hamper the market growth. Despite much development and modernization, there is still a lack of awareness associated with reproductive health. There are weird social customs and ignorant behaviors. Thus, this restraints the market growth.
- High Cost
The huge expenditure associated with the treatment of hormone fertility surely hamper the market growth.
This global polycystic ovary syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global polycystic ovary syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Polycystic Ovary Syndrome Market Scope
The global polycystic ovary syndrome market is segmented on the basis of condition, complication, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Condition
- Irregular Periods
- Excess Androgen
- Polycystic Ovaries
- Others
Complication
- Infertility
- Metabolic Syndrome
- Sleep Apnea
- Endometrial Cancer
- Depression
- Others
Treatment
- Medication
- Surgery
- Others
Route of Administration
- Oral
- Parenteral
- Implants
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Polycystic Ovary Syndrome Market Regional Analysis/Insights
The global polycystic ovary syndrome market is analysed and market size insights and trends are provided by condition, complications, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global polycystic ovary syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global polycystic ovary syndrome market throughout the forecasted period due to increasing initiatives taken by the government and pharmaceutical organizations to spread awareness and presence of generic manufacturer.
North America dominates the market due to increasing hormones related diseases, in women’s and increasing initiatives taken by the pharmaceutical organizations to generate novel formulation.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Polycystic Ovary Syndrome Market Share Analysis
The global polycystic ovary syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global polycystic ovary syndrome market.
Key players operating in the global polycystic ovary syndrome market include:
- Pfizer Inc. (U.S.)
- Merck KGaA (Germany)
- Sanofi (France)
- Biocare Medical, LLC (U.S.)
- Lilly (U.S.)
- Teva Pharmaceutical Industries (Israel)
- Mitsubishi Chemical Group Corporation (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- Par Pharmaceutical (U.S.)
- TerSera Therapeutics LLC (U.S.)
- General Electric (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- Allergan (Ireland)
- Alcon (Switzerland)
- Astellas Pharma Inc. (Japan)
SKU-